StreetInsider.com News Articles

Form 10-Q ABBOTT LABORATORIES For: Jun 30

Tue, 28 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260728/26826894.html

Form 10-Q ABBOTT LABORATORIES For: Jun 30

Tue, 28 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260728/26826894.html

Abbott Labs (ABT) PT Lowered to $125 at UBS

Tue, 28 Jul 2026 08:55:24 -0400

UBS analyst Patrick Wood lowered the price target on Abbott Labs (NYSE: ABT) to $125.00 (from $135.00) while maintaining a Buy rating.

FDA approves Freenome's blood-based colorectal cancer screening test

Mon, 27 Jul 2026 08:00:38 -0400

Freenome (Nasdaq: FRNM) and Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration has approved SimpleScreen CRC, a blood-based screening test for colorectal cancer in adults aged 45 and older who are at average risk for the disease. Abbott will exclusively commercialize the test in the U.S. beginning this fall.

The test detects signals associated with colorectal cancer from cell-free DNA in the blood. In the PREEMPT CRC clinical validation study, conducted at more than 200 sites with over 48,000 participants, SimpleScreen CRC detected colorectal cancer with 81.1% sensitivity and showed 90.4% specificity for advanced colorectal neoplasia. Sensitivity for

FDA approves Freenome's blood-based colorectal cancer screening test

Mon, 27 Jul 2026 08:00:38 -0400

FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

Mon, 27 Jul 2026 08:00:00 -0400

– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening –

– Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening –

BRISBANE, Calif. and ABBOTT PARK, Ill., July 27, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, and Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved SimpleScreen™ CRC, a new blood-based screening option for colorectal cancer (CRC) in

FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

Mon, 27 Jul 2026 08:00:00 -0400

– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening –

– Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening –

FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

Mon, 27 Jul 2026 08:00:00 -0400

– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening –

– Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening –

FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

Mon, 27 Jul 2026 08:00:00 -0400

– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening –

– Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening –

Abbott Labs (ABT) Reiterated at Buy by Benchmark After Q2 Model Updates

Mon, 20 Jul 2026 07:26:59 -0400

Benchmark analyst Bruce D. Jackson reiterated a Buy rating and $120.00 price target on Abbott Labs (NYSE: ABT).

The analyst commented, "We are updating our model for 2Q. Management raised annual Adjusted EPS guidance to $5.45-5.60 (was $5.38- 5.58) and maintained annual comparable revenue growth expectations of 6.5-7.5%. Comparable growth excludes foreign currency impact and rebases the prior year for the Exact Sciences acquisition. We are raising our 2026 revenue forecast to $50.194 billion from $49.963 billion and our Adjusted EPS estimate rises to $5.53 from $5.48 a share. We assume comparable revenue growth of 6.6% and foreign currency exchange impact

Abbott Labs (ABT) PT Raised to $117 at Bernstein SocGen Group

Fri, 17 Jul 2026 08:48:39 -0400

Bernstein SocGen Group analyst Lee Hambright raised the price target on Abbott Labs (NYSE: ABT) to $117.00 (from $110.00) while maintaining a Outperform rating.

Abbott Labs (ABT) Reiterated at Buy by Benchmark After Q2 Revenue Beat

Fri, 17 Jul 2026 07:36:04 -0400

Benchmark analyst Bruce D. Jackson reiterated a Buy rating and $120.00 price target on Abbott Labs (NYSE: ABT).

The analyst commented, "Abbott Labs reported 2Q Adjusted EPS of $1.31 on revenue of $12.593 Billion, which was ahead of our estimates of $1.28 / $12.603 Billion and Consensus of $1.28 / $12.523 Billion, respectively. The company had guided to 2Q Adjusted EPS of $1.25 to $1.31. Management raised annual Adjusted EPS guidance to $5.45-5.60 (was $5.38-5.58) and maintained annual comparable revenue growth expectations of 6.5-7.5%. Comparable growth excludes foreign currency impact and rebases the prior year for the Exact Sciences acquisition. Growth

Abbott Labs (ABT) PT Raised to $120 at JPMorgan

Fri, 17 Jul 2026 07:24:56 -0400

JPMorgan analyst Robbie Marcus raised the price target on Abbott Labs (NYSE: ABT) to $120.00 (from $110.00) while maintaining a Overweight rating.

Abbott Labs (ABT) PT Raised to $118 at Piper Sandler

Fri, 17 Jul 2026 06:46:43 -0400

Piper Sandler analyst Adam Maeder raised the price target on Abbott Labs (NYSE: ABT) to $118.00 (from $115.00) while maintaining a Overweight rating.

Abbott Labs (ABT) PT Raised to $112 at Wells Fargo

Fri, 17 Jul 2026 06:42:18 -0400

Wells Fargo analyst Larry Biegelsen raised the price target on Abbott Labs (NYSE: ABT) to $112.00 (from $109.00) while maintaining a Overweight rating.

Abbott Labs (ABT) PT Raised to $134 at BTIG

Thu, 16 Jul 2026 16:00:55 -0400

(Updated - July 16, 2026 4:00 PM EDT)

BTIG analyst Marie Thibault raised the price target on Abbott Labs (NYSE: ABT) to $134.00 (from $131.00) while maintaining a Buy rating.

The analyst commented: "Abbott shares were up ~11% in Thursday trading following a solid Q2 result, maintained 2026 sales guide, and increased full-year adj. EPS outlook that demonstrated broad-based strength and added confidence to the 2H26 outlook (see our flash note on Q2 headline results here). Importantly, management emphasized strong underlying demand for healthcare as a whole with some forward-looking insight from Diagnostic testing volumes and cited robust performance in its U.S.

Abbott Labs (ABT) PT Raised to $134 at BTIG

Thu, 16 Jul 2026 16:00:55 -0400

(Updated - July 16, 2026 4:00 PM EDT)

BTIG analyst Marie Thibault raised the price target on Abbott Labs (NYSE: ABT) to $134.00 (from $131.00) while maintaining a Buy rating.

Abbott beats second-quarter estimates, raises 2026 guidance

Thu, 16 Jul 2026 07:43:35 -0400

Investing.com -- Abbott (NYSE:ABT) shares are trading higher premarket on Thursday after the company reported second-quarter earnings, topping consensus expectations and raising its full-year earnings guidance.

Adjusted earnings per share came in at $1.31, exceeding the analyst estimate of $1.28, as the healthcare company posted revenue of $12.59 billion, surpassing the consensus estimate of $12.52 billion. Revenue increased 13.0% on a reported basis and 4.8% on a comparable basis compared to the same quarter last year.

The company raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to its previous range of $5.38 to $5.58. The midpoint

Abbott beats second-quarter estimates, raises 2026 guidance

Thu, 16 Jul 2026 07:43:35 -0400

The company raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to its previous range of $5.38 to $5.58. The midpoint

Abbott beats second-quarter estimates, raises 2026 guidance

Thu, 16 Jul 2026 07:43:35 -0400

The company raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to its previous range of $5.38 to $5.58. The midpoint

Form 8-K ABBOTT LABORATORIES For: Jul 16

Thu, 16 Jul 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20260716/26776741.html

Form 8-K ABBOTT LABORATORIES For: Jul 16

Thu, 16 Jul 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20260716/26776741.html

Abbott (ABT) Tops Q2 EPS by 3c; offers guidance

Thu, 16 Jul 2026 07:32:30 -0400

Abbott (NYSE: ABT) reported Q2 EPS of $1.31, $0.03 better than the analyst estimate of $1.28. Revenue for the quarter came in at $12.59 billion versus the consensus estimate of $12.52 billion.

GUIDANCE:

Abbott sees FY2026 EPS of $5.45-$5.60, versus the consensus of $5.48.

For earnings history and earnings-related data on Abbott (ABT) click here.

Abbott (ABT) Tops Q2 EPS by 3c; offers guidance

Thu, 16 Jul 2026 07:32:30 -0400

Abbott (NYSE: ABT) reported Q2 EPS of $1.31, $0.03 better than the analyst estimate of $1.28. Revenue for the quarter came in at $12.59 billion versus the consensus estimate of $12.52 billion.

GUIDANCE:

Abbott sees FY2026 EPS of $5.45-$5.60, versus the consensus of $5.48.

For earnings history and earnings-related data on Abbott (ABT) click here.

Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Thu, 16 Jul 2026 07:30:00 -0400

Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent
Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31
Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%¹
Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58
Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchases

ABBOTT PARK, Ill., July 16, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second